Biotechnology · NBIX

“The decrease in research and development expenses of approximately $5.7 million for the three months ended June 30, 2026 compared to the three months ended June 30, 2025, was primarily attributable to the following: • a decrease of $8.4 million in other research and development expenses is driven by lower cost for BIIB122/DNL151 and DNL343; partially offset by increased purchasing of raw materials at our large molecule manufacturing facility in Salt Lake City, Utah; • an increase of $2.8 million in TV programs external research and development expenses is driven by manufacturing expenses and clinical expenses for zafinofusp alfa; partially offset by lower manufacturing expenses for DNL628, and lower clinical expense for tividenofusp alfa.”

DNLI 10-Q · 2026-08-06

“Results of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 Revenues Net Product Sales Three Months Ended September 30, Nine Months Ended September 30, ( in millions) 2025 2024 2025 2024 INGREZZA $ 686.6 $ 612.9 $ 1,856.2 $ 1,698.4 CRENESSITY 98.1 — 165.8 — Other 5.2 3.7 13.6 11.0 Total net product sales $ 789.9 $ 616.6 $ 2,035.6 $ 1,709.4 Compared with the comparable periods last year, the increase for the third quarter and first nine months of 2025 primarily reflected increased net product sales of INGREZZA, driven by total prescriptions on strong patient demand partially offset by lower net price due to new market access investments to support long-term growth, and CRENESSITY, which was launched in the U.S. as a first-in-class FDA-approved treatment of CAH in December 2024.”

NBIX 10-Q · 2025-10-28

“In addition, the increase for the first nine months of 2025 was partially offset by decreased impairment charges associated with our vacated legacy campus facilities.”

NBIX 10-Q · 2025-10-28